Search Results - "Vorla, Mounica"

Refine Results
  1. 1

    Molecular Pathways in Pulmonary Arterial Hypertension by Shah, Aangi J., Vorla, Mounica, Kalra, Dinesh K.

    “…Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular…”
    Get full text
    Journal Article
  2. 2

    New Drugs and Therapies in Pulmonary Arterial Hypertension by Shah, Aangi J, Beckmann, Taylor, Vorla, Mounica, Kalra, Dinesh K

    “…Pulmonary arterial hypertension is a chronic, progressive disorder of the pulmonary vasculature with associated pulmonary and cardiac remodeling. PAH was a…”
    Get full text
    Journal Article
  3. 3

    Meta-Analysis of the Safety and Efficacy of Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus by Vorla, Mounica, Kalra, Dinesh K

    Published in Pharmaceuticals (Basel, Switzerland) (30-05-2024)
    “…Literature on the preferred anticoagulant for treating left ventricular thrombus (LVT) is lacking. Thus, our objective was to compare the efficacy of DOACs…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes by Beckmann, Taylor, Shelley, Patrisha, Patel, Darshan, Vorla, Mounica, Kalra, Dinesh K

    Published in Pharmaceuticals (Basel, Switzerland) (01-10-2022)
    “…Pulmonary hypertension (PH) is characterized by a resting mean pulmonary artery pressure (PAP) of 20 mmHg or more and is a disease of multiple etiologies. Of…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    Abstract 13431: Safety and Efficacy of Pulmonary Artery Denervation Therapy for the Treatment of Pulmonary Artery Hypertension by Vorla, Mounica, Akbar, Usman, Rallabhandi, Sai Sri Harsha, Shastri, Dipsa, Chitteti, Aditi, Yandrapalli, Srikanth

    Published in Circulation (New York, N.Y.) (07-11-2023)
    “…Abstract only Background: Despite recent advances in the treatment of pulmonary arterial hypertension (PAH), the survival rate remains poor in severe PAH…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13

    Sglt2 Inhibitors In Women And Cardiovascular Outcomes - Meta-analysis Of Sex Differences In Eleven Randomized Clinical Trials by Shah, Aangi J., Vorla, Mounica, Jafri, S. Hammad, Kalra, Dinesh K.

    Published in Journal of cardiac failure (01-01-2024)
    “…Cardiovascular (CV) diseases with their ensuing morbidity and mortality have traditionally been underappreciated in women. Women have been underrepresented in…”
    Get full text
    Journal Article
  14. 14

    Myocarditis associated with COVID-19 and its vaccines - a systematic review by Rout, Amit, Suri, Sarabjeet, Vorla, Mounica, Kalra, Dinesh K.

    Published in Progress in cardiovascular diseases (01-09-2022)
    “…Since the beginning of the COVID-19 (Coronavirus Disease of 2019) pandemic, myocarditis has received much attention and controversy as one of the more…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Dyslipidemia in Human Immunodeficiency Virus Disease by Kalra, Dinesh K., Vorla, Mounica, Michos, Erin D., Agarwala, Anandita, Virani, Salim, Duell, P. Bart, Raal, Frederick J.

    “…The advent of newer and better tolerated antiretroviral therapy has progressively shortened the life expectancy gap between people living with HIV (PWH) and…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20